Investigating the Therapeutic Potential of Two Novel Protein Degraders Targeting STAT3 and CBP/p300 in Multiple Myeloma
Background: Multiple myeloma (MM) remains an incurable plasma-cell malignancy in which disease persistence is sustained not only by tumour-intrinsic oncogenic programmes but also by protective cues from the bone marrow microenvironment (BMME). In particular, cytokine-driven STAT3 signalling and CBP/p300-dependent enhan...